New biologic injection takes on steroids for rotator cuff pain — but study pulled

NCT ID NCT06712290

Terminated Symptom relief Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study aimed to compare a single injection of connective tissue matrix (CTM) against a standard corticosteroid shot for treating rotator cuff tendinopathy. Participants would have been randomly assigned to one of the two injections and followed for six months with questionnaires and physical tests. However, the study was withdrawn before enrolling any patients, so no data were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Connective tissue matrix (CTM) injection
What this could lead to: If it works, this could offer a biologic alternative to steroid injections for shoulder pain, potentially with fewer side effects.
What could go wrong: This trial was withdrawn before enrolling any participants, so no results exist. The approach is very early and unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ROTATOR CUFF TENDINOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease of the tendon rotator cuff syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ROTATOR CUFF TENDINOPATHY

Contacts and locations

Locations

Allegheny Health Network Federal North Medical Office Building

Pittsburgh, Pennsylvania, 15212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.